Aditya Vinay Vaze, MD
Cardiovascular Disease (Cardiology) · Castro Valley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 2
Offices
2 locations · University Healthcare Alliance · Stanford Health Care
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Vaze’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A155492 · Current
Licensed to practise in California · since 2018 · expires 2027-07-31 · Albany Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$226,994
Medicare paid this office $226,994 for 1,027 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 350 | $51,598 | $103 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 373 | $45,001 | $118 |
| New patient visit (45+ min) | 239 | $31,854 | $133 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 66 | $24,073 | $365 |
| Long return visit (40+ min) | 102 | $19,122 | $148 |
See all 27 services
| Return visit (30+ min) | 350 | $51,598 | $103 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 373 | $45,001 | $118 |
| New patient visit (45+ min) | 239 | $31,854 | $133 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 66 | $24,073 | $365 |
| Long return visit (40+ min) | 102 | $19,122 | $148 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 352 | $6,922 | $15 |
| New patient visit (60+ min) | 37 | $6,552 | $177 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 50 | $5,104 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 227 | $3,460 | $13 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 24 | $3,255 | $136 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 50 | $3,108 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 371 | $2,749 | $7 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 102 | $2,320 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 35 | $2,088 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,817 | $70 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 17 | $1,036 | $61 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 18 | $729 | $26 |
| Injection, regadenoson, 0.1 mg | 48 | $672 | None |
| Programming of dual lead pacemaker system | 13 | $553 | $37 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 56 | $444 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 32 | $395 | $12 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 19 | $383 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 19 | $358 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 26 | $297 | $11 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $257 | $18 |
| Heart rhythm recording of continous external ekg over 8-15 days | 16 | $199 | $12 |
| Injection, aminophyllin, up to 250 mg | 21 | $155 | None |
Procedures Medicare counted
| Pacemaker insertion or repair | 1-10 | None |
Who their Medicare patients are
1,027 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 14% · Women 55% · Also on Medicaid 25% · Health risk score 1.47. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 33% · Diabetes 30% · Chronic kidney disease 30% · Atrial fibrillation 26% · Heart failure 22% · Depression 22% · Cancer 20% · COPD 16% · Stroke 12% · Dementia 9%.
The office billed $1,224,627, Medicare allowed $288,937 and paid $226,994; for 3,436 services of 56 kinds; $826 of it was for drugs given in the office and $226,168 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,027 | 3,436 | 75 | 1.47 | $1,224,627 | $226,994 |
| 2023 | 112 | 155 | 67 | 2.80 | $22,934 | $4,663 |
| 2022 | 86 | 111 | 69 | 1.56 | $15,204 | $2,791 |
| 2021 | 35 | 41 | 67 | 1.40 | $7,753 | $1,288 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 80 | $640 | $7 |
2022: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 53 | $371 | $6 |
2021: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 26 | $181 | $6 |
Medicaid work
$5,525 in 2024
Medicaid paid $5,525 for 381 billed services this clinician did in 2024, up to 99 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 186 | $2,143 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 53 | $1,910 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 115 | $779 |
| Return visit (30+ min) | 15 | $616 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 12 | $77 |
| 2024 | 381 | 5 | 99 | $5,525 |
| 2023 | 467 | 1 | 77 | $1,454 |
| 2022 | 427 | 1 | 68 | $1,697 |
| 2021 | 208 | 1 | 58 | $763 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 467 | $1,454 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 427 | $1,697 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 208 | $763 |
Drugs they prescribed that Part D paid
$456,247
Pharmacies billed $456,247 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,554) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,330 generic and fewer than 11 brand-name prescriptions · $456,247 in drug cost · 17 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 73 | $91,912 | $1,259 |
| Entresto | 28 | $39,723 | $1,419 |
| Xarelto | 24 | $32,632 | $1,360 |
| Brilinta | 23 | $19,281 | $838 |
| Jardiance | 18 | $12,865 | $715 |
See all 26 drugs
| Eliquis | 73 | $91,912 | $1,259 |
| Entresto | 28 | $39,723 | $1,419 |
| Xarelto | 24 | $32,632 | $1,360 |
| Brilinta | 23 | $19,281 | $838 |
| Jardiance | 18 | $12,865 | $715 |
| Metoprolol | 213 | $2,558 | $12 |
| Amiodarone | 79 | $1,829 | $23 |
| Atorvastatin | 143 | $1,723 | $12 |
| Rosuvastatin | 92 | $1,129 | $12 |
| Diltiazem 24hr Er (Cd) | 29 | $1,083 | $37 |
| Carvedilol | 121 | $1,008 | $8 |
| Furosemide | 142 | $955 | $7 |
| Isosorbide Mononitrate Er | 46 | $898 | $20 |
| Flecainide Acetate | 26 | $885 | $34 |
| Bumetanide | 13 | $541 | $42 |
| Losartan | 52 | $511 | $10 |
| Potassium Chloride | 12 | $466 | $39 |
| Nitroglycerin | 41 | $441 | $11 |
| Amlodipine Besylate | 70 | $425 | $6 |
| Metoprolol | 51 | $413 | $8 |
| Clopidogrel | 17 | $360 | $21 |
| Midodrine | 11 | $344 | $31 |
| Ezetimibe | 16 | $253 | $16 |
| Spironolactone | 21 | $163 | $8 |
| Lisinopril | 24 | $151 | $6 |
| Hydrochlorothiazide | 13 | $73 | $6 |
Year by year
| 2024 | 1,554 | 484 | 0% (0) | None | $456,247 |
| 2023 | 914 | 281 | 0% (0) | None | $298,167 |
| 2022 | 774 | 244 | 0% (0) | None | $283,808 |
| 2021 | 128 | 62 | 0% (0) | None | $15,098 |
| 2020 | 55 | 16 | 0% (0) | 31% | $9,486 |
| 2018 | 69 | 23 | 0% (0) | None | $3,095 |
| 2017 | 113 | 25 | None | 17% | $2,714 |
| 2016 | 75 | 43 | None | 16% | $1,623 |
| 2015 | 30 | 17 | 0% (0) | None | $1,048 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Jardiance | 19 | $16,331 | $860 |
| Pradaxa | 21 | $6,136 | $292 |
| Amiodarone | 93 | $2,832 | $30 |
| Metoprolol | 124 | $2,048 | $17 |
| Atorvastatin | 74 | $1,437 | $19 |
| Flecainide Acetate | 30 | $1,010 | $34 |
| Diltiazem 24hr Er (Cd) | 36 | $910 | $25 |
| Furosemide | 77 | $907 | $12 |
| Isosorbide Mononitrate Er | 32 | $883 | $28 |
| Rosuvastatin | 51 | $869 | $17 |
| Clopidogrel | 38 | $636 | $17 |
| Metoprolol | 54 | $533 | $10 |
| Carvedilol | 30 | $344 | $11 |
| Lisinopril | 23 | $264 | $11 |
| Sotalol | 12 | $262 | $22 |
| Atenolol | 13 | $247 | $19 |
| Losartan | 18 | $227 | $13 |
| Spironolactone | 13 | $135 | $10 |
2022: 16 drugs
| Brilinta | 26 | $22,027 | $847 |
| Pradaxa | 28 | $13,324 | $476 |
| Amiodarone | 63 | $2,376 | $38 |
| Metoprolol | 98 | $1,650 | $17 |
| Atorvastatin | 80 | $1,493 | $19 |
| Metoprolol | 73 | $715 | $10 |
| Clopidogrel | 35 | $664 | $19 |
| Isosorbide Mononitrate Er | 29 | $602 | $21 |
| Rosuvastatin | 33 | $563 | $17 |
| Furosemide | 49 | $554 | $11 |
| Flecainide Acetate | 12 | $479 | $40 |
| Cephalexin | 28 | $298 | $11 |
| Lisinopril | 23 | $260 | $11 |
| Warfarin | 14 | $230 | $16 |
| Carvedilol | 19 | $226 | $12 |
| Nitroglycerin | 14 | $191 | $14 |
2021: 2 drugs
| Metoprolol | 21 | $412 | $20 |
| Cephalexin | 20 | $204 | $10 |
2020: 2 drugs
| Eliquis | 14 | $8,808 | $629 |
| Carvedilol | 16 | $112 | $7 |
2017: 2 drugs
| Metoprolol | 21 | $276 | $13 |
| Atorvastatin | 23 | $182 | $8 |
Money from drug and device companies
$103 in 2025
| 2025 | 4 | 4 | None | $103 |
| 2024 | 1 | 1 | None | $22 |
| 2022 | 1 | 1 | None | $60 |
| 2021 | 3 | 6 | None | $368 |
| 2020 | 2 | 2 | None | $43 |
| 2019 | 4 | 12 | None | $297 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Leqvio | $33 | 1 payment
|
| Medtronic | Venaseal | $25 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $24 | 1 payment
|
| Boston Scientific | Lux-Dx Insertable Cardiac Monitor | $21 | 1 payment
|
See all 4 published payments
| Medtronic | Meals · 2025-12-15 | Venaseal | $25 |
| Novartis Pharmaceuticals | Meals · 2025-10-17 | Leqvio | $33 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-08-06 | Lifevest | $24 |
| Boston Scientific | Meals · 2025-07-29 | Lux-Dx Insertable Cardiac Monitor | $21 |
See earlier years (2024, 2022, 2021, 2020, 2019)
2024: $22
| Boston Scientific | None | $22 | 1 payment
|
2022: $60
| Cepheid | None | $60 | 1 payment
|
2021: $368
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $201 | 3 payments
|
| Boston Scientific | Zoom | $109 | 2 payments
|
| Biotronik | Solia | $58 | 1 payment
|
2020: $43
| Boston Scientific | General - Therapies | $24 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Pradaxa | $19 | 1 payment
|
2019: $297
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $239 | 8 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $23 | 2 payments
|
| Lantheus Medical Imaging | Definity | $21 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Pradaxa | $14 | 1 payment
|
Professional record
- NPI
- 1356737530
- Licence
- CA A155492California A155492: Current · expires 2027-07-31
- Trained
- Albany Medical College of Union University, 2015
- Group
- University Healthcare Alliance · Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 20126 Stanton Ave Ste 100, Castro Valley, CA, 94546
- NPI first listed
- 2015-04-14
- NPI last updated
- 2024-06-10
- NPI record certified
- 2024-06-10
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.